A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO)

  • End date
    Mar 27, 2026
  • participants needed
  • sponsor
    Hoffmann-La Roche
Updated on 24 October 2022
follicular lymphoma
b-cell lymphoma
aggressive non-hodgkin's lymphoma


This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).

Condition Non-Hodgkin Lymphoma
Treatment Rituximab, Gemcitabine, Oxaliplatin, Tocilizumab, Polatuzumab Vedotin, Mosunetuzumab
Clinical Study IdentifierNCT05171647
SponsorHoffmann-La Roche
Last Modified on24 October 2022


Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
Life expectancy of at least 12 weeks
CD20+ aggressive lymphoma as determined by the local hemopathology laboratory from the following diagnoses by 2016 World Health Organization classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS); high-grade B-cell lymphoma (NOS or double/triple hit); trFL R/R to standard therapies to trFL; FL3B
Received at least one prior systemic therapy for aggressive non-Hodgkin's lymphoma (aNHL)
Have either relapsed or have become refractory to a prior regimen must meet the following criteria: relapsed to prior regimen(s) after having a documented history of response (CR or PR) of at least 6 months in duration from completion of regimen(s); refractory to any prior regimen, defined as no response to the prior therapy, or progression within 6 months of completion of the last dose of therapy
Participants who have received only one prior line of therapy must be ineligible for autologous stem cell transplant (ASCT)
Measurable disease, defined as at least 1 bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least 1 bi-dimensionally measurable extra nodal lesion, defined as > 1.0 cm in its longest dimension
Have a pathology report for the initial histopathology diagnosis and the most recent histopathology diagnosis prior to entering the study
Representative tumor specimen and the corresponding pathology report available for confirmation of diagnosis as well as for biomarker analysis
Adequate hepatic, hematologic, and renal function

Exclusion Criteria

Pregnant or breast feeding, or intending to become pregnant during the study or within 3 months after the final dose of mosunetuzumab, 9 months after the final dose of polatuzumab vedotin, 12 months after the final dose of rituximab, 6 months after the final dose of gemcitabine, 9 months after the final dose of oxaliplatin, and 3 months after the final dose of tocilizumab, as applicable
Inability to comply with protocol-mandated activity restrictions
Prior treatment with mosunetuzumab or other CD-20-directed bispecific antibodies, polatuzumab vedotin, or R-GemOx or Gem-Ox
Contraindication to any component of the study treatment
Grade > 1 peripheral neuropathy
Received anti-lymphoma treatments with monoclonal antibodies, radio-immunoconjugates or antibody-drug conjugates (ADCs) within 4 weeks before the first dose of study treatment
Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to the first dose of study treatment
Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment
ASCT within 100 days prior to the first study treatment administration
Prior treatment with chimeric antigen receptor (CAR) T cell therapy within 30 days before the first study treatment administration
Prior allogenic stem cell transplant (SCT)
Have had a solid organ transplantation
Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
History of confirmed progressive multifocal leukoencephalopathy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombination antibody-related fusion proteins)
History of malignancy that has been treated with curative intent within >/= 2 years prior to screening, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.. 5-year overall survival rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage 1 uterine cancer
Currently have or have had a past history of central nervous system (CNS) involvement of lymphoma
History of CNS disease which was symptomatic or required treatment in the past 1 year, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina
Significant active pulmonary disease
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of the nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to the first study treatment administration
Known or suspected chronic active Epstein-Barr virus (EBV) infection
Recent major surgery within 4 weeks prior to the first study treatment administration
Positive test results for chronic hepatitis B infection
Acute or chronic hepatitis C virus (HCV) infection
History of HIV infection
Have been administered a live, attenuated vaccine within 4 weeks before the first dose of study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
History of autoimmune disease
Received systemic immunosuppressive medications (including, but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents) with the exception of corticosteroid treatment </= 10 mg/day prednisone or equivalent within 2 weeks prior to first dose of study treatment
Received investigational therapy, whether or not intended for lymphoma treatment, within 7 days prior to initiation of study treatment
Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
Any serious medical condition or abnormality in clinical laboratory tests that precludes the participant's safe participation in and in the completion of the study, or which could affect compliance with the protocol or interpretation of results
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note